Evidence map›Paper›PMID 36890806›Full record

ArticleInterventional cardiology (London, England)2022

Effects of High- or Moderate-intensity Rosuvastatin on 1-year Major Adverse Cardiovascular Events Post-percutaneous Coronary Intervention.

Morteza Chehrevar, Reza Golchin Vafa, Mohammadhossein Rahmani, Mohammadjavad Mehdizadeh Parizi, Amin Ahmadi, Bardia Zamiri, Reza Heydarzadeh, Mohammad Montaseri, Seyed Ali Hosseini, Javad Kojuri

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Interventional cardiology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Morteza ChehrevarCardiology Department, Shiraz University of Medical Sciences Shiraz, Iran.
Reza Golchin VafaProfessor Kojuri Cardiology Clinic Shiraz, Iran.
Mohammadhossein RahmaniProfessor Kojuri Cardiology Clinic Shiraz, Iran.
Mohammadjavad Mehdizadeh PariziProfessor Kojuri Cardiology Clinic Shiraz, Iran.
Amin AhmadiProfessor Kojuri Cardiology Clinic Shiraz, Iran.
Bardia ZamiriProfessor Kojuri Cardiology Clinic Shiraz, Iran.
Reza HeydarzadehProfessor Kojuri Cardiology Clinic Shiraz, Iran.
Mohammad MontaseriProfessor Kojuri Cardiology Clinic Shiraz, Iran.
Seyed Ali HosseiniStudent Research Committee, Shiraz University of Medical Sciences Shiraz, Iran.
Javad KojuriCardiology Department, Shiraz University of Medical Sciences Shiraz, Iran.
Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

coronary artery diseasemajor adverse cardiovascular eventPercutaneous coronary interventionstable anginastatin therapy

Identifiers

PMID36890806
PMCPMC9987507
OpenAlexW4313523205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.